POSLUMA PET Scans to Find Significant Prostate Cancer in Unclear MRI Findings
Tests POSLUMA PET scans in men with unclear prostate MRI findings needing biopsy.
Key facts
- Who runs it
- SimonMed Imaging
- Where
- Avondale, Chandler, Mesa, Phoenix, Scottsdale, and Surprise, United StatesSee the 6 sites
- Trial code
- Registry title
- POSLUMA PET Imaging for PI-RADS 3 Prostate Lesions
- Status
- Not yet recruiting
- People taking part
- 130 people, planned
- Starts
- 1 Dec 2026
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- PET Imaging with Flotufolastat F 18
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with a PI-RADS 3 lesion on a recent MRI who are due to have a prostate biopsy. They will have a research-only POSLUMA PET scan first.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- A PI-RADS 3 lesion found on a multiparametric MRI within the past 4 weeks
- Earlier treatment
- No prior diagnosis or treatment of prostate cancer
Main reasons for not taking part
- Prior diagnosis or treatment of prostate cancer
- PI-RADS 4 or 5 lesion
- Negative MRI (PI-RADS 1 or 2)
- Cannot have a PSMA PET scan or prostate biopsy
- Cannot have both MRI and CT
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Male, age 18 years or older
- PI-RADS 3 lesion diagnosed by multiparametric MRI within the past 4 weeks
- Clinical indication for prostate biopsy
- Undergoing targeted biopsy and systematic biopsy as part of the routine clinical pathway
- Able to provide written informed consent
Who cannot take part
- Prior diagnosis or treatment of prostate cancer
- Any medical condition that may interfere with study procedures
- PI-RADS 4 or 5 lesion
- Negative MRI, defined as PI-RADS 1 or 2
- Contraindication to PSMA PET or prostate biopsy
- Contraindication to both MRI and CT
Where in United States
- SimonMed Imaging - AkosAvondale, United StatesContact: Xiaowei HongNot yet recruiting
- SimonMed Imaging - Chandler SouthChandler, United StatesContact: Xiaowei HongNot yet recruiting
- SimonMed Imaging - GreenfieldMesa, United StatesContact: Xiaowei HongNot yet recruiting
- SimonMed Imaging - Central PhoenixPhoenix, United StatesContact: Xiaowei HongNot yet recruiting
- SimonMed Imaging - KierlandScottsdale, United StatesContact: Xiaowei HongNot yet recruiting
- SimonMed Imaging - Surprise Stadium VillageSurprise, United StatesContact: Xiaowei HongNot yet recruiting
About the trial
What the trial wants to find out
This prospective, multicenter diagnostic accuracy study will evaluate whether POSLUMA (flotufolastat F 18) PET/MRI or PET/CT can detect clinically significant prostate cancer, defined as Gleason score 7 or higher, in adult men with PI-RADS 3 lesions on recent multiparametric MRI and a clinical indication for prostate biopsy. Participants will undergo a research-only POSLUMA PET scan before targeted and systematic prostate biopsy. PET imaging metrics and clinical variables will be compared with histopathology. Research PET results will not be used to guide clinical management or replace standard diagnostic procedures.
The group in the trial
- POSLUMA PET Diagnostic ImagingTreatment being tested
Participants undergo one research-only POSLUMA PET/MRI or PET/CT before targeted and systematic prostate biopsy.
Treatment: PET Imaging with Flotufolastat F 18
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Targeting the Gray Zone: Early Detection of Clinically Significant Prostate Cancer in PI-RADS 3 Patients Using PET Imaging With an 18F-Labeled Radiohybrid PSMA-Targeted Imaging Agent
- Plain-language title
- POSLUMA PET Scans to Find Significant Prostate Cancer in Unclear MRI FindingsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026